Possibilities for therapeutic drug monitoring of azathioprine: 6- thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells

Therapeutic Drug Monitoring

Volumn 19, Issue 3, 1997, Pages 318-326

  Bergan, S ^b   Rugstad, H E ^a   Klemetsdal, B ^a   Giverhaug, T ^c   Bentdal, O ^c   Sodal G ^c   Hartmann, A ^a   Aarbakke, J ^c   Stokke, O ^c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

6 Thioguanine nucleotides; Azathioprine; Renal transplantation; Thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; FUROSEMIDE; PREDNISOLONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ARTICLE; DRUG MONITORING; ENZYME ACTIVITY; ENZYME ANALYSIS; ERYTHROCYTE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; DRUG MONITORING; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METHYLTRANSFERASES; MIDDLE AGED; THIONUCLEOTIDES;

EID: 0031450479     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199706000-00013     Document Type: Article

References (24)

1. Lindholm A, Albrechtsen D, Flatmark A, et al. A randomized multicenter trial of cyclosporin and prednisolone versus cyclosporin, azathioprine, and prednisolone following primary living donor renal transplantation. Transpl Int 1994;7:207-15.
2. Kliem V, Repp H, Frei U. Long-term improvement of chronic renal graft dysfunction in cyclosporine-treated patients by addition of azathioprine and reduction of cyclosporine. Transplant Proc 1994;26:2553-5.
3. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
4. Bergan S, Rugstad HE, Bentdal O, Stokke O. Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes. Transplantation 1994;58:803-8.
5. Schütz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995; 27:1298-300.
6. Thorogood J, Persijn GG, Schreuder TGM, et al. The effect of HLA matching on kidney graft survival in separate post-transplantation intervals. Transplantation 1990;50:146-50.
7. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
8. Vogt MH, Stet EH, De Abreu RA, Bokkerink JP, Lambooy LH, Trijbels FJ. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993;1181:189-94.
9. Pazmiño PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980;28:356-67.
10. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
11. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996;49:393-396.
12. Grinyo J, Groth C, Pichlmayr R, et al. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-5.
13. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987;423:169-78.
14. Bergan S, Rugstad HE, Bentdal O, Endresen L, Stokke O. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit 1994;16:13-20.
15. Weinshilboum RM, Raymond FA, Pazmiño PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85:323-33.
16. Klemetsdal B, Straume B, Wist E, Aarbakke J. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol 1993;44:147-52.
17. Klemetsdal B, Straume B, Lysaa R, Giverhaug T, Aarbakke J. Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol 1995;48:495-9.
18. Vartdal F, Gaudernack G, Funderud S, et al. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation: a fast and reliable technique. Tissue Antigens 1986;28:301-12.
19. Gardner MJ, Altman DG, eds. Statistics with confidence. London: British Medical Journal, 1989.
20. Lennard L, van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
21. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
22. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-6.
23. Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 1995;60:639-42.
24. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.